Fig. 4

Microglial depletion increases the amount of HA in the cerebral cortex. (a) ELISA-based quantification of HA in the soluble (Sol) and insoluble (Ins) fractions prepared from the control and PLX groups. n = 5 mice. Control: Sol 4.17 ± 0.85, Ins 23.94 ± 1.63; PLX: Sol 6.16 ± 0.53, Ins 26.45 ± 0.25. (b) Percentage of HA in the Sol and Ins fractions. n = 5 mice. Control: Sol 14.73 ± 1.95, Ins 85.27 ± 1.95; PLX: Sol 18.87 ± 1.32, Ins 81.13 ± 1.32 (c) Agarose gel electrophoresis and Stains-all staining of HA isolated from the soluble and insoluble fractions of the control and PLX groups. HA std: molecular mass standards of HA. (d) Normalized staining intensity profiles and mobilities of HA std (top), soluble HA (middle), and insoluble HA (bottom). The size distribution peaks of soluble and insoluble HA are indicated. Mean ± SD (shaded area). n = 4 mice. (e) mRNA expression levels of HA synthases and HA degrading enzymes in the control and PLX groups. n = 4 mice. Has1: Control 1.00 ± 0.20, PLX 1.08 ± 0.20; Has2: Control 1.00 ± 0.42, PLX 0.51 ± 0.19; Has3: Control 1.00 ± 0.20, PLX 1.01 ± 0.16; Hyal1: Control 1.00 ± 0.61, PLX 2.00 ± 0.45; Hyal2: Control 1.00 ± 0.22, PLX 0.93 ± 0.14; Hyal3: Control 1.00 ± 0.23, PLX 0.89 ± 0.10; Hybid: Control 1.00 ± 0.14, PLX 0.98 ± 0.28; Tmem2: Control 1.00 ± 0.18, PLX 1.12 ± 0.13. The error bars represent the SD. Statistical analysis was performed by an independent t-test; * indicates p < 0.05.